UNASSIGNED: The prevalence of @entity101 is increasing among younger @entity1 , and new strategies are needed to identify high-risk @entity1 who should be targets for early intervention. Several mechanisms underlying @entity101 might also contribute to @entity3010 ( @entity3010 ), but whether @entity1 with @entity3010 have a higher risk of subsequently developing @entity101 has not been assessed. We prospectively evaluated this possibility in a substudy of the Nurses' Health Study II. @entity1 were 1,257 @entity1 with clinically significant @entity3010 (1991-2005) and 2,463 age-matched comparison @entity1 with few menstrual symptoms. @entity1 were followed for incident @entity101 until 2011. Over 6-20 years, @entity101 was reported by 342 @entity1 with @entity3010 and 541 @entity1 without. After adjustment for age, smoking, body mass index, and other risk factors for @entity101 , @entity1 with @entity3010 had a hazard ratio for @entity101 of 1.4 (95% confidence interval: 1.2, 1.6) compared with @entity1 without @entity3010 . Risk was highest for @entity101 that occurred before 40 years of age (hazard ratio = 3.3; 95% confidence interval: 1.7, 6.5; P for interaction = 0.0002). The risk associated with @entity3010 was not modified by use of @entity7280 or antidepressants but was attenuated among @entity1 with high intakes of @entity9138 and @entity8728 (P < 0.05). These results suggest that @entity3010 might be associated with future development of @entity101 and that this risk may be modifiable.

XXXX and Subsequent Risk of @entity101 in a Prospective Study.

@entity1 :: ('9606', 'Species') :: ['women', 'Participants'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity9138 :: ('MESH:D013831', 'Chemical') :: ['thiamine'] @entity3010 :: ('MESH:D011293', 'Disease') :: ['PMS', 'premenstrual syndrome'] @entity7280 :: ('MESH:D003276', 'Chemical') :: ['oral contraceptives'] @entity8728 :: ('MESH:D012256', 'Chemical') :: ['riboflavin']
@entity3010 :: (MESH:D011293,Disease) :: ['Premenstrual Syndrome']
